Instability of p53 in renal cell carcinoma (RCC) has not been previously associated with mutations, because 96% of clearcell RCC samples in the database were present with the p53 wild type. 1 However, inhibition of a major p53 regulator in humans doubles minute 2 homolog (HDM2) induced cell cycle arrest but not cell death in RCC. 2 Therefore, overcoming p53 instability is a major issue in RCC treatment.
Recently, our group 3 and others 4 have found that the expression level of transglutaminase 2 (TGase 2, E.C. 2.1.2.13) is generally elevated in most RCC cell lines, which deplete p53 into aggregates in the autophagosome, resulting in p53 depletion through autophagy. 3 This p53 instability by TGase 2 regulation allows tumor cells to evade apoptosis and grow remarkably.
TGase 2 is an enzyme that catalyzes an isopeptide bond between protein glutamine and lysine residues, resulting in a covalent cross-link. 5 In normal physiological conditions, TGase 2 contributes toward regulating apoptosis from intruders or damages, including biological, chemical and physical challenges. 6 However, TGase 2 knockout mice display impaired autophagy under starvation, 7 although TGase 2 knockout mice present with an otherwise normal life. 8, 9 Cancer cells adopt TGase 2 mediated autophagy for survival.
TGase 2 competes with HDM2 for binding to p53; promotes autophagy-dependent p53 degradation in RCC cell lines under starvation; and binds to p53 and p62 simultaneously without ubiquitin-dependent recognition of p62. The bound complex does not have cross-linking activity. A binding assay using a series of deletion mutants of p62, p53 and TGase 2 revealed that the PB1 domain of p62 (residues 85-110) directly interacts with the β-barrel domains of TGase 2 (residues 592-687), whereas the HDM2-binding domain (transactivation domain, residues 15-26) of p53 interacts with the N-terminus of TGase 2 (residues 1-139).
1 During translocation of p53 to the autophagosome through TGase 2 binding, cross-linking activity is not needed. This finding is in agreement with the observation that TGase 2 crosslinking activity occurs only in the autophagosome during autophagy. 1, 7 This suggests that TGase 2 acts as a chaperone of p53 with a cross-linking catalytic activity. This interaction may result in rapid autophagy without consuming energy to tag ubiquitin on p53, as p62 is known to interact with ubiquitinated proteins (see Figure 1 ). This autophagy process is beneficial in which it supplies building blocks, including degraded p53, for cancer cells.
We recently reported that monotherapy using the TGase 2 inhibitor GK921 in a xenograft tumor model abrogated RCC growth through p53 stabilization. 10 In addition to the increase in p53 stability due to TGase 2 inhibition, the administration of a DNA-damaging anti-cancer drug such as doxorubicin, remarkably induced apoptosis in RCC cell lines and sensitively reduced tumor volume in a xenograft model. 
